Apellis Pharmaceuticals Inc Forward P/E
What is the Forward P/E of Apellis Pharmaceuticals Inc?
The Forward P/E of Apellis Pharmaceuticals Inc is -11.54
What is the definition of Forward P/E?
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Forward P/E of companies in the Health Care sector on NASDAQ compared to Apellis Pharmaceuticals Inc
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Companies with forward p/e similar to Apellis Pharmaceuticals Inc
- Biostage has Forward P/E of -12.00
- Immunovant Inc has Forward P/E of -11.92
- U.S. Xpress Enterprises Inc has Forward P/E of -11.88
- CollPlant Biotechnologies Ltd has Forward P/E of -11.63
- Oncocyte has Forward P/E of -11.63
- Parrot SA has Forward P/E of -11.57
- Apellis Pharmaceuticals Inc has Forward P/E of -11.54
- Biostage has Forward P/E of -11.43
- Soligenix Inc has Forward P/E of -11.34
- Abivax SA has Forward P/E of -11.32
- GrowGeneration Corp has Forward P/E of -11.31
- Obalon Therapeutics Inc has Forward P/E of -11.30
- Cassava Sciences Inc has Forward P/E of -11.29